title: Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells.
abstract: Anti-estrogens like hydroxytamoxifen (OHT) have mixed agonist/antagonist activities, leading to tissue-specific stimulation of cellular proliferation. Partial agonist activity of OHT can be observed in vitro in endometrial carcinoma cells like Ishikawa. Here, we have compared several anti-estrogens (including extensively characterized OHT and pure anti-estrogens such as ICI164, 384 and RU58,668, which are devoid of uterotrophic activity) for their capacity to stimulate promoters containing estrogen response elements (EREs) or AP1-binding sites (12-O-tetradecanoylphorbol-13-acetate response elements, TREs), the two types of DNA motifs known to mediate transcriptional stimulation by estrogen receptors. Assays were performed in Ishikawa cells either by transient transfection or by using cell lines with stably propagated reporter vectors. In transient transfection experiments, none of the anti-estrogens displayed agonist activity on the promoters tested. In contrast, significant transcriptional stimulation was observed with low concentrations of OHT and RU39,411 in Ishikawa cells stably propagating reporter constructs containing a minimal ERE3-TATA promoter. In addition, micromolar concentrations of OHT, but not of RU39,411, stimulated stably propagated AP1-responsive reporter constructs. No transcriptional stimulation of ERE- or TRE-containing promoters was observed with the pure anti-estrogens ICI164,384 and RU58,668. These results indicate that the presence of estrogen response elements in promoters is sufficient to mediate cell-specific agonism of anti-estrogens at the transcriptional level, and that stimulation of AP1 activity may be restricted to a subset of anti-estrogens possessing agonist activity on EREs. In addition, our results suggest that transient transfections do not fully recapitulate in vivo conditions required to observe agonist activity of anti-estrogens.
authors.affiliation: Département de Biochimie, Université de Montréal, Montréal, Québec, Canada H3C 3J7.
authors.forename: A
authors.initials: A
authors.lastname: Barsalou
authors.forename: W
authors.initials: W
authors.lastname: Gao
authors.forename: S I
authors.initials: SI
authors.lastname: Anghel
authors.forename: J
authors.initials: J
authors.lastname: Carrière
authors.forename: S
authors.initials: S
authors.lastname: Mader
mesh_terms: D000818:Animals; D001483:Base Sequence; D019556:COS Cells; D002460:Cell Line; D004591:Electrophoresis, Polyacrylamide Gel; D004717:Endometrium / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology*; D004967:Estrogens / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D053284:Polyunsaturated Alkamides; D011401:Promoter Regions, Genetic; D011980:Receptors, Progesterone / Q000235:genetics; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000494:pharmacology; D014158:Transcription, Genetic / Q000187:drug effects; D014407:Tumor Cells, Cultured; D005466:Fluorocarbons
chemical_list: D004958:Estradiol; D004965:Estrogen Antagonists; D004967:Estrogens; D053284:Polyunsaturated Alkamides; D011980:Receptors, Progesterone; D013629:Tamoxifen; C086511:RU 58668; D005466:Fluorocarbons; C016601:afimoxifene; C051781:ICI 164384